LEADER 03671nam 2200769z- 450 001 9910557380603321 005 20231214132940.0 035 $a(CKB)5400000000042093 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76940 035 $a(EXLCZ)995400000000042093 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aSmall Cell Lung Cancer: A New Era Is Beginning? 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (150 p.) 311 $a3-0365-2301-4 311 $a3-0365-2302-2 330 $aSmall-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody?drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques. 517 $aSmall Cell Lung Cancer 606 $aMedicine$2bicssc 610 $aimmune checkpoint inhibitors 610 $aextensive-stage small cell lung cancer 610 $anivolumab 610 $aipilimumab 610 $apembrolizumab 610 $aatezolizumab 610 $adurvalumab 610 $achemotherapy 610 $asmall-cell lung cancer 610 $alobectomy 610 $apneumonectomy 610 $aradiotherapy 610 $amultimodal treatment 610 $aimmunotherapy 610 $aSCLC 610 $aPARP 610 $aDDR 610 $aICB 610 $asynthetic lethality 610 $aSLFN11 610 $aSTING 610 $apathology and classification of SCLC 610 $abiology of SCLC 610 $aimmune-checkpoint inhibitors in SCLC 610 $asmall cell lung cancer 610 $aImmunotherapy 610 $aextensive disease 610 $alurbinectedin 610 $agene pathway 610 $apathobiology 610 $atargeted therapy 610 $acirculating tumor cells 610 $aprognostic biomarker 610 $atargeted agents 615 7$aMedicine 700 $aMorabito$b Alessandro$4edt$01326702 702 $aRolfo$b Christian$4edt 702 $aMorabito$b Alessandro$4oth 702 $aRolfo$b Christian$4oth 906 $aBOOK 912 $a9910557380603321 996 $aSmall Cell Lung Cancer: A New Era Is Beginning$93037687 997 $aUNINA